Zhongguo Fei Ai Za Zhi. 2024 Jul 20;27(7):485-494. doi: 10.3779/j.issn.1009-3419.2024.102.27.
The standard clinical practice of managing the non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations was elaborated in Chinese expert consensus on non‑small cell lung cancer with EGFR exon 20 insertion mutations (2023 edition), and this rare subset has gradually attracted attention recently. With the deepening of treatment area exploration and the approval of new targeted drugs, there are more options for the diagnosis and treatment of EGFR ex20ins positive NSCLC patients. Therefore, based on the previous version of consensus, the expert panel has updated this consensus on the standardized clinical diagnosis and treatment of EGFR ex20ins mutation NSCLC through reference to literature and clinical data, and combined with the experts' own clinical experience. The updated recommendations includes disease congnition, testing methods, therapy and recent relevant clinical trials for NSCLC patients with EGFR ex20ins mutation, in order to provide better medication reference for clinical physicians. .
《中国表皮生长因子受体（EGFR）外显子20插入（ex20ins）突变非小细胞肺癌诊疗专家共识（2023年版）》阐述了非小细胞肺癌（NSCLC）伴EGFR外显子20插入突变的标准临床诊疗实践，这一罕见亚组近来逐渐受到关注。随着治疗领域探索的深入以及新靶向药物的获批，EGFR ex20ins阳性NSCLC患者的诊断和治疗有了更多选择。因此，专家小组在前一版共识的基础上，通过参考文献和临床数据，并结合专家自身临床经验，对EGFR ex20ins突变NSCLC的标准化临床诊疗共识进行了更新。更新后的推荐内容涵盖了EGFR ex20ins突变NSCLC患者的疾病认知、检测方法、治疗以及近期相关临床试验，旨在为临床医生提供更好的用药参考。
